New scan could spot breast cancer spread without surgery
NCT ID NCT06695039
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special PET scan using a radioactive tracer called FES can accurately detect breast cancer that has spread to lymph nodes under the arm. Researchers will scan 71 people with estrogen-positive breast cancer and compare the results to standard methods. If the scan works well, it may help doctors decide on treatment without needing invasive biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluoroestradiol (18F) injection
- What this could lead to
- If successful, this could provide a more accurate, non-invasive way to detect breast cancer spread to lymph nodes, potentially reducing unnecessary surgeries.
- What could go wrong
- This is a small, early-phase study (71 people) focused on diagnostic accuracy, not treatment. The results may not apply to all patients or change current practice without larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER INVASIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tailored radiation may spare breast cancer patients from arm swelling
- Can a smart light beam help surgeons remove every last cancer cell?
- New combo approach for breast cancer: reconstruction and radiation together
- Can a simple blood test help predict breast Cancer's next move?
- Fingernail moons may reveal who responds to breast cancer therapy
- Small study aims to predict which breast cancer patients benefit from immunotherapy